https://www.selleckchem.com/pr....oducts/nvp-bgt226.ht
001) with the highest rate (78%) in the HR-/HER2+ group. Overall, HER2+ patients had a significantly higher AXpCR than HER2- subtypes (66% versus 28% P0.001). HR and HER2 status were also predictive of AXpCR when comparing patient, tumor, and treatment variables. Biologic subtype better correlated with rates of AXpCR than nodal burden alone with the highest rates of AXpCR in HER2+ patients. Consideration of tumor biology is more informative than nodal burden when evaluating options for axillary management after NAC. Biologic subt
Like
Comment
Share
